cbdMD Inc banner
C

cbdMD Inc
AMEX:YCBD

Watchlist Manager
cbdMD Inc
AMEX:YCBD
Watchlist
Price: 0.9336 USD 1.81%
Market Cap: $9.8m

cbdMD Inc
Investor Relations

cbdMD, Inc. engages in the business of operating cannabidiol brands such as Paw cannabidiol and cbdMD botanicals. The company is headquartered in Charlotte, North Carolina and currently employs 90 full-time employees. The company went IPO on 2017-11-17. The firm owns and operates CBD brands cbdMD, Paw CBD and cbdMD Botanicals. Its cbdMD brand of products includes a range of premium every day and functional CBD products, including tinctures; gummies; topicals; capsules; drink mixes; and sleep, focus and calming aids.Its Paw CBD brand of products includes a line of veterinarian-formulated products including tinctures, chews, topicals products in varying strengths and formulas. Its cbdMD Botanicals brand of beauty and skincare products features facial oil and serum, toners, moisturizers, clear skin, facial masks, exfoliants and body care stock-keeping units (SKU). cbdMD, Paw CBD and cbdMD Botanicals products are distributed through its e-commerce websites, third party ecommerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers. Its products are sold through www.cbdmd.com, www.pawcbd.com, and cbdmdbotanicals.com Websites.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q1 2026
Call Date
Feb 17, 2026
AI Summary
Q1 2026

Revenue Growth: cbdMD reported $5 million in revenue for the quarter, up 12% sequentially, marking three consecutive quarters of revenue growth.

Gross Margin: Gross margin was 60%, down from 66% last year, primarily due to higher warehouse costs and a greater wholesale mix.

Bluebird Acquisition: The company completed the acquisition of Bluebird Botanicals, adding incremental revenue, IP, and a new customer base, with integration and synergy extraction now underway.

Balance Sheet: Liquidity improved with $3.4 million in cash and $5.4 million in working capital, supported by a $2.25 million Series C financing and a new $20 million equity line of credit.

Regulatory Environment: Management highlighted ongoing regulatory challenges but expressed optimism about bipartisan legislative efforts and the company's strong compliance position.

Key Financials
Revenue
$5 million
Gross Margin
60%
Loss from Operations
$286,000
Net Loss Attributable to Common Shareholders
$325,000
Net Loss Per Share
$0.04 per share
Adjusted EBITDA Loss
$36,000
Cash and Cash Equivalents
$3.4 million
Working Capital
$5.4 million
Operating Cash Flow
($812,000)
Earnings Call Recording
Other Earnings Calls

Management

Mr. T. Ronan Kennedy
Interim CEO, CFO & Principal Executive Officer
No Bio Available
Dr. Sibyl Swift Ph.D.
CSO, VP of Regulatory Affairs & Director
No Bio Available
Mr. Bradley Whitford
Chief Accounting Officer, Treasurer & Secretary
No Bio Available
Zeb Booker
Chief Technology Officer
No Bio Available
Mr. Lance Blundell
General Counsel
No Bio Available
Robert Pettway
Director of Public Relations
No Bio Available
Mr. Francisco Mangual
Senior VP of Sales
No Bio Available
Ms. Shannon Charles
Chief Marketing Officer
No Bio Available
Mr. David Johnson
Senior VP of Business Development
No Bio Available

Contacts

Address
NORTH CAROLINA
Charlotte
8845 Red Oak Blvd
Contacts
+17044453060
www.cbdmd.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett